DR. STACY GREENE M.D.
Prescription History 1003820721
Internal Medicine - Infectious Disease in New Orleans, LA
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. STACY GREENE M.D., an active Infectious Disease specialist practicing in New Orleans, LA. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 144 documented patient claims. Among these therapy options, the most frequently utilized medication is Biktarvy, which accounts for 54 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2023)Rx (2023) | Avg Cost per FillCost / Fill | Vs. Other LA PrescribersVs. LA Avg |
|---|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 54 | $3,873.67▼ below LA avg | ▼ Less than typical |
About Biktarvy: This combination product is used by itself to help control HIV infection. Show more ▾ It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details. In 2023, this provider wrote 54 Medicare prescriptions for Biktarvy, about 60% of the volume of the typical Louisiana prescriber of this medication (90). Medicare paid an average of $3,873.67 per fill, versus $3,884.83 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average LA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the LA average for this medication. 54 30-Day Fills standardized to 30-day supplies 1,620 Days of Medication total across all patients in 2023 | |||
| VemlidyTenofovir Alafenamide | 28 | $1,442.08 | ≈ Typical |
About Vemlidy: Tenofovir alafenamide is used to treat chronic hepatitis B infection, a viral infection of the liver. Show more ▾ It works by stopping or slowing the growth of the virus. Chronic hepatitis infection can lead to serious liver damage (cirrhosis) and liver cancer. It is not known if tenofovir alafenamide can cure hepatitis B or can prevent you from passing the virus to others. Practice safer sex (such as the use of latex condoms) to lower the risk of passing the virus to others. In 2023, this provider wrote 28 Medicare prescriptions for Vemlidy, about 88% of the volume of the typical Louisiana prescriber of this medication (32). Medicare paid an average of $1,442.08 per fill, versus $1,390.42 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average LA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 28 30-Day Fills standardized to 30-day supplies 840 Days of Medication total across all patients in 2023 | |||
| CabenuvaCabotegravir/Rilpivirine | 23 | $6,171.11 | ≈ Typical |
About Cabenuva: This product is used to help control HIV infection. Show more ▾ It contains 2 medications: cabotegravir and rilpivirine. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Cabotegravir is an integrase inhibitor while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Both drugs block the virus from growing and infecting more cells. Cabotegravir/rilpivirine is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details. In 2023, this provider wrote 23 Medicare prescriptions for Cabenuva, about the same volume as the typical Louisiana prescriber of this medication (21). Medicare paid an average of $6,171.11 per fill, versus $5,868.34 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average LA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 23 30-Day Fills standardized to 30-day supplies 680 Days of Medication total across all patients in 2023 | |||
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $2,174.02▼ below LA avg | ▼ Less than typical |
About Descovy: This product is used with other HIV medications to help control HIV infection. Show more ▾ It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: emtricitabine and tenofovir alafenamide. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. They are often called NRTIs. This product should not be used by itself to help control HIV infection. Doing so can make your treatment less effective. Use combination treatment with at least one other HIV medication. This product is also approved in the US to help prevent HIV infection in people who have a high risk for infection. Some things that increase risk include having a partner infected with HIV, having unprotected sex, having multiple sex partners, infection with a sexually transmitted disease-STD, or use/abuse of drugs or alcohol. Emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details. In 2023, this provider wrote 15 Medicare prescriptions for Descovy, about a quarter of the volume of the typical Louisiana prescriber of this medication (54). Medicare paid an average of $2,174.02 per fill, versus $2,197.20 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average LA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the LA average for this medication. 15 30-Day Fills standardized to 30-day supplies 424 Days of Medication total across all patients in 2023 | |||
| TivicayDolutegravir Sodium | 13 | $2,124.89▼ below LA avg | ▼ Less than typical |
About Tivicay: Dolutegravir is used with other HIV medications to help control HIV infection. Show more ▾ It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Dolutegravir belongs to a class of drugs known as integrase inhibitors. It blocks the virus from growing and infecting more cells. Dolutegravir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details. In 2023, this provider wrote 13 Medicare prescriptions for Tivicay, about 19% of the volume of the typical Louisiana prescriber of this medication (69). Medicare paid an average of $2,124.89 per fill, versus $2,316.42 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average LA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the LA average for this medication. 13 30-Day Fills standardized to 30-day supplies 364 Days of Medication total across all patients in 2023 | |||
| ApretudeCabotegravir | 11 | $3,480.13 | – No State Data |
About Apretude: This product is used to help reduce the risk of getting HIV infection. Show more ▾ Cabotegravir belongs to a class of drugs known as integrase inhibitors. It works by blocking the virus from growing and infecting more cells. This product does not protect against other sexually transmitted infections (such as gonorrhea, syphilis). When cabotegravir is given in combination with rilpivirine, it is used to help control HIV infection. To decrease your risk of getting HIV and other sexually transmitted infections, use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details. In 2023, this provider wrote 11 Medicare prescriptions for Apretude. Medicare paid an average of $3,480.13 per fill. No state comparison is available for this medication. How often this provider prescribes it No state benchmark is available for this medication. What Medicare paid per fill $3,480.13 Cost per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 11 30-Day Fills standardized to 30-day supplies 330 Days of Medication total across all patients in 2023 | |||
About this data. The prescription history for DR. STACY GREENE M.D. is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2023, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Infectious Disease prescribing approach at this New Orleans, LA practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average volume among LA prescribers of the same medication. Always confirm current medications and costs directly with the provider and your plan.
